Latest Updates
Suboxone case acquisition for law firms remains one of the more cost-efficient mass tort intake opportunities available in mid-2026, with a claimant pool that is still largely unpenetrated despite MDL 3092 carrying more than 3,000 active plaintiffs. The FDA's 2022 black-box warning on Suboxone's sublingual film formulation gives plaintiff firms a durable causation anchor that compresses early litigation risk. Bellwether trials are approaching, which means acquisition costs will rise as outcomes clarify, making the current window strategically significant for firms building their docket.
That does not mean it is without complexity. The plaintiff population carries some screening friction, and case values remain unproven while discovery runs its course. This post breaks down the litigation landscape, the acquisition economics, and the intake process so your firm can make an informed decision about whether to enter now, wait, or pass.
The Litigation Landscape: What MDL 3092 Means for Case Value and Timing
MDL 3092 is consolidated in the Northern District of Ohio before Judge Dan Polster, a name plaintiff attorneys recognize from the national opioid MDL. Polster runs an efficient docket. The MDL formed in 2023, Indivior is the primary defendant, and Aquestive Therapeutics (which developed the sublingual film delivery system) is a co-defendant.
As of now, the MDL sits at 3,000+ active plaintiffs. That number sounds large, but it is still relatively small for a nationwide product-liability MDL. Compare it to the talc, CPAP, or Zantac dockets at comparable stages and the current plaintiff count looks modest given the actual scope of Suboxone film prescribing across the country. That gap between actual injured claimants and filed cases is where the opportunity lives for firms that move before the docket becomes crowded.
No verdicts have been returned yet. Bellwether trials are projected for 2025 to 2026. Settlements are not on the table at this stage, which is expected. Defendants rarely open settlement discussions before bellwether results give both sides a pricing benchmark. The practical implication for your firm: cases signed today will likely be in the pipeline 18 to 36 months before any meaningful resolution economics become visible. That is a normal horizon for this stage of a growing MDL. Firms that treat it as a reason to wait often find themselves priced out of the acquisition market once settlement chatter starts and every firm in the plaintiff bar pivots to the same docket simultaneously.
The liability theory is strong. Suboxone sublingual film dissolves under the tongue at a highly acidic pH, which directly erodes dental enamel. Buprenorphine also reduces saliva production, compounding the damage. Indivior's internal studies allegedly showed dental risks before the product launched. The 2022 FDA safety communication, which was later elevated to a black-box warning, functions as a near-public admission that the drug-dental injury connection is real and foreseeable. Failure-to-warn cases with FDA-mandated warnings are not bulletproof, but they are substantially easier to litigate than cases built entirely on expert causation testimony.
Claimant Pool and Market Demand: Is There Still Volume to Capture?
Suboxone film has been prescribed nationwide since the mid-2000s. Prescribing volume is highest in Appalachia, the Midwest, and rural communities with elevated opioid treatment need, but this is a true nationwide docket. Every state has meaningful prescribing history.
Estimates on the addressable claimant pool vary, but given the scale of the opioid crisis and the years Suboxone film was prescribed without a dental warning, the number of people who took the sublingual film for six or more months and experienced significant dental injury likely runs well into the tens of thousands. The FDA warning was issued in January 2022. Many patients and even their treating physicians are still unaware that the film, not just general health factors, may have caused or accelerated their dental problems. That awareness gap is actually good for acquisition right now: demand from claimants who have connected the dots is rising but has not peaked.
Saturation among plaintiff firms is currently low to moderate. This tort does not have the media saturation of Camp Lejeune or the chest-thumping ad spend that surrounded Roundup at its peak. Firms entering the space now are not fighting over the same claimant who has already seen twelve ads from twelve different firms. That changes the economics favorably, both on ad cost and on signed-case quality.
One honest friction point: the plaintiff population includes people in opioid recovery, which adds intake complexity. It does not make cases invalid or unwinnable. It does mean your qualification and documentation process needs to be thoughtful. More on that below.
Suboxone Case Acquisition for Law Firms: Advertising Economics and Channel Strategy
On realistic cost-per-lead and cost-per-signed-case figures, the numbers right now are favorable compared to mature torts. Facebook and Instagram remain the dominant paid channels for Suboxone film campaigns. The claimant profile skews toward users who are active on social platforms, and the visual storytelling format works well for dental injury narratives without veering into claimant-recruitment territory that creates bar-compliance issues.
Cost per lead on Facebook is currently running in the $30 to $65 range for well-optimized campaigns, depending on geographic targeting and creative quality. Cost per signed retainer, after intake filtering, is running in the $400 to $900 range for firms with tight intake processes. Those numbers will climb as more firms enter the docket. The window at the low end of that range is not permanent.
Creative angles that convert focus on the FDA warning itself as a news-style hook, the disconnect between trusting a prescribed medication and experiencing unexpected dental damage, and the distinction between the sublingual film and the tablet formulation. That last point matters operationally: only the film form carries the dental injury claim. Campaigns that do not make that distinction waste budget on leads who used the tablet.
YouTube pre-roll, programmatic display, and TikTok are secondary channels worth testing depending on your budget. Search (Google) performs for demand capture once brand awareness has been built, but at this stage of the docket, paid social is doing the heavy awareness lifting.
At MTAA, we have managed more than $250 million in Facebook ad spend for 600+ plaintiff law firms across 100+ mass torts. Our model is transparent cost-plus pricing: you pay actual ad spend plus a 15% management fee, no inflated media markups. For Suboxone, we are running full campaign management for firms that want to enter the market without building the infrastructure internally. The creative, targeting, compliance review, and optimization are handled. Firms stay focused on intake and litigation.
Intake and Qualification: How to Build a Signed Case That Sticks
Screening Suboxone film cases has a few non-negotiable checkpoints. First, confirm the claimant used the sublingual film, not the tablet. The injury mechanism is specific to the film. Second, confirm duration of use: six months or more is the general threshold for establishing that meaningful exposure occurred. Third, get a picture of the dental injury clearly tied to the period of film use. Significant prior dental problems do not automatically disqualify a case, but they complicate damages and need to be documented accurately upfront, not discovered later during defense review.
Medical and dental records are going to be central to these cases. Your intake and retainer flow should include a records authorization as early in the process as possible. Firms that wait until months after signing to pull records are going to find cases falling out of their docket when the documentation does not match what the claimant reported.
The opioid recovery context deserves a straightforward intake approach rather than a cautious one. These are valid claimants with real injuries. The key is building an intake script and questionnaire that captures the facts cleanly, documents the timeline of Suboxone use against the timeline of dental injury, and gives your paralegals a clear scoring framework. AI-assisted intake tools are increasingly useful here for flagging inconsistencies early and prioritizing cases for attorney review. If your firm is not yet using AI in intake, the operational efficiency argument alone is worth exploring. I wrote "A Lawyer's Guide to AI" specifically for plaintiff firms thinking through where AI creates real leverage and where the hype outpaces the utility.
How MTAA Approaches This Docket
We are actively running Suboxone film campaigns for plaintiff firms and the early data is solid. The creative testing phase confirmed that the FDA warning hook outperforms generic dental injury messaging by a significant margin. Geographic targeting toward the Midwest and Appalachian regions delivers stronger lead quality, as measured by intake-to-sign conversion, than broad national campaigns. That said, broad national campaigns still produce volume at acceptable CPL for firms that want scale over precision.
Our intake partners are seeing strong retainer conversion rates when firms use a two-touch intake process: an initial qualification call followed by a short document request before the retainer is sent. Firms that push the retainer at the end of the first call are seeing higher fall-off during the records phase. A small process change with meaningful downstream impact on signed-case retention.
The Bottom Line on Suboxone Case Acquisition for Law Firms
This is an early-stage MDL with a strong liability theory, an addressable and growing claimant pool, and acquisition economics that are still favorable before the docket reaches critical mass. Bellwether trials in 2025 to 2026 will price the cases and trigger the settlement conversations that make everyone pay attention. Firms that have built a clean docket of well-documented Suboxone film cases before that moment are in the best position to benefit from it.
Suboxone case acquisition for law firms is not a bet-the-firm opportunity, but it is a legitimate docket-building play for plaintiff firms that want exposure to a product-liability MDL at the right stage of development. The combination of the FDA black-box warning, a defined injury mechanism, a named defendant with resources, and a judge who knows how to move an MDL makes this one worth serious evaluation. If your firm wants to talk through the acquisition math or get campaigns running, that is exactly what MTAA is built to do.
Ready to Build Your Caseload?
Get a free campaign analysis from Mass Tort Ad Agency.
$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.
Schedule a Free Consultation →Frequently Asked Questions: Advertising Suboxone Tooth Decay Cases
Where does Suboxone tooth decay stand in the MDL lifecycle, and is there still time for firms to build a meaningful docket?
MDL 3092 is consolidated in the Northern District of Ohio under Judge Dan Polster, with 3,000+ active plaintiffs and bellwether trials projected for 2025 to 2026, placing it in active discovery rather than end-stage settlement. That timing is favorable for firms entering now, as the liability anchor, a 2022 FDA black-box warning on dental decay, is already established, and docket positions can still be built before competition tightens around bellwether outcomes.
What does it cost to acquire a signed Suboxone tooth decay case, and how should firms think about the acquisition economics?
Signed case costs vary by channel and screening model, but firms working with cost-plus media partners, where spend is transparent and margins are fixed rather than marked up, typically see signed case costs that are meaningfully lower than comparable MDLs at the same litigation stage. Because the claimant pool carries some screening friction around documented dental injury and Suboxone prescription history, firms should model intake conversion rates carefully before committing to a flat cost-per-case arrangement with a lead vendor.
Is the available claimant pool large enough to justify a sustained acquisition campaign, or has the addressable market already been captured by early-moving firms?
The addressable claimant pool remains substantial: Suboxone sublingual film has been prescribed to millions of patients for opioid use disorder treatment, and awareness of the dental injury litigation among eligible claimants is still relatively low compared to more publicized mass torts. Competition among plaintiff firms is lower than in comparable MDLs at the same stage, which means a well-funded acquisition campaign now faces less bidding pressure and can accumulate docket volume before the market saturates post-bellwether.
Which advertising channels and creative strategies are most effective for signing Suboxone tooth decay cases, and what does a cost-plus media model look like in practice?
Social media platforms, particularly Facebook and Instagram, combined with targeted search campaigns have shown strong performance for Suboxone intake because the claimant demographic is reachable through interest and behavioral targeting tied to addiction recovery content. A cost-plus media model means the agency charges a transparent, fixed fee on top of actual ad spend with no markup on media, giving the firm full visibility into true cost-per-lead and signed-case economics rather than blended rates that obscure acquisition efficiency.
What are the primary screening criteria firms should build into their intake process to ensure cases meet the liability threshold for MDL 3092?
Qualifying cases generally require documented use of Suboxone sublingual film (not tablets), onset of dental decay or tooth loss occurring during or after use, and ideally a prescribing or treatment record that ties the injury timeline to the film formulation. Firms should build intake scripts and retainer workflows that capture prescription history and dental records early, as cases lacking documentation of both the product and the injury create downstream value risk when cases are evaluated for bellwether selection or settlement tiering.
